Detalhe da pesquisa
1.
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
JTO Clin Res Rep
; 5(2): 100637, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361741